Literature DB >> 16108815

Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.

Yoshinori Ikarashi1, Akira Iizuka, Yumie Koshidaka, Yuji Heike, Yoichi Takaue, Mitsuzi Yoshida, Mitchell Kronenberg, Hiro Wakasugi.   

Abstract

Invariant Valpha14 natural killer T (Valpha14i NKT) cells are a unique immunoregulatory T-cell population that is restricted by CD1d. The glycolipid alpha-galactosylceramide (alpha-GalCer) is presented by CD1d and causes robust Valpha14i NKT-cell activation. Three days after injection of alpha-GalCer, Valpha14i NKT cells vigorously increase in number and then gradually decrease to normal levels. In the present study, we found that the re-administration of alpha-GalCer into mice primed 3 days earlier causes a marked increase in serum interleukin-4 and interferon-gamma. Intracellular staining revealed that the only expanded Valpha14i NKT cells are responsible for the enhanced cytokine production. The enhanced cytokine production was correlated with an increased number of Valpha14i NKT cells after priming. Additionally, primed Valpha14i NKT cells produced larger amounts of cytokine as compared with naive Valpha14i NKT cells when cultured with alpha-GalCer-pulsed dendritic cells. Thus, we considered that a subset of expanded Valpha14i NKT cells acquired a strong ability to produce cytokines. In contrast to mice primed 3 days earlier, cytokine production is markedly diminished in mice primed 7 days earlier. The expanded Valpha14i NKT cells altered the surface phenotype (NK1.1- CD69-) and contained intracellular interferon-gamma. Additionally, we found that primed Valpha14i NKT cells did not disappear or down-regulate surface TCR expression when re-injected with alpha-GalCer as compared with naive Valpha14i NKT cells. These results demonstrate that the function and surface phenotype of Valpha14i NKT cells is dramatically altered after alpha-GalCer priming.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108815      PMCID: PMC1802404          DOI: 10.1111/j.1365-2567.2005.02193.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells.

Authors:  G Eberl; H R MacDonald
Journal:  Eur J Immunol       Date:  2000-04       Impact factor: 5.532

Review 2.  NKT cells: facts, functions and fallacies.

Authors:  D I Godfrey; K J Hammond; L D Poulton; M J Smyth; A G Baxter
Journal:  Immunol Today       Date:  2000-11

3.  Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

Authors:  G Eberl; P Brawand; H R MacDonald
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

4.  NKT cells and tumor immunity--a double-edged sword.

Authors:  M J Smyth; D I Godfrey
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

5.  Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.

Authors:  R Nakagawa; I Nagafune; Y Tazunoki; H Ehara; H Tomura; R Iijima; K Motoki; M Kamishohara; S Seki
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

6.  Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.

Authors:  Y Osman; T Kawamura; T Naito; K Takeda; L Van Kaer; K Okumura; T Abo
Journal:  Eur J Immunol       Date:  2000-07       Impact factor: 5.532

7.  Cytokines production of U5A2-13-positive T cells by stimulation with glycolipid alpha-galactosylceramide.

Authors:  M Azuma; K Kato; Y Ikarashi; R Asada-Mikami; H Maruoka; Y Takaue; A Saito; H Wakasugi
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

8.  Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes.

Authors:  M C Leite-de-Moraes; A Herbelin; C Gouarin; Y Koezuka; E Schneider; M Dy
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

9.  Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.

Authors:  Hans J J van der Vliet; Johan W Molling; Nobusuke Nishi; Allan J Masterson; Wendy Kölgen; Steven A Porcelli; Alfons J M van den Eertwegh; B Mary E von Blomberg; Herbert M Pinedo; Giuseppe Giaccone; Rik J Scheper
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

10.  Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.

Authors:  J L Matsuda; O V Naidenko; L Gapin; T Nakayama; M Taniguchi; C R Wang; Y Koezuka; M Kronenberg
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more
  8 in total

1.  Reduction of CD1d expression in vivo minimally affects NKT-enhanced antibody production but boosts B-cell memory.

Authors:  Gillian A Lang; Amy M Johnson; T Scott Devera; Sunil K Joshi; Mark L Lang
Journal:  Int Immunol       Date:  2011-03-12       Impact factor: 4.823

2.  Reconstitution models to evaluate natural killer T cell function in tumor control.

Authors:  Simon Gebremeskel; Drew Slauenwhite; Brent Johnston
Journal:  Immunol Cell Biol       Date:  2015-06-22       Impact factor: 5.126

3.  PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.

Authors:  Vrajesh V Parekh; Saif Lalani; Sungjune Kim; Ramesh Halder; Miyuki Azuma; Hideo Yagita; Vipin Kumar; Lan Wu; Luc Van Kaer
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

4.  Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice.

Authors:  Sungjune Kim; Saif Lalani; Vrajesh V Parekh; Tiffaney L Vincent; Lan Wu; Luc Van Kaer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

Review 5.  Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.

Authors:  Sungjune Kim; Saif Lalani; Vrajesh V Parekh; Lan Wu; Luc Van Kaer
Journal:  Expert Rev Vaccines       Date:  2008-12       Impact factor: 5.217

6.  Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers.

Authors:  T Scott Devera; Hemangi B Shah; Gillian A Lang; Mark L Lang
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

7.  Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-γ.

Authors:  T Sakurai; A Inamine; T Iinuma; U Funakoshi; S Yonekura; D Sakurai; T Hanazawa; T Nakayama; Y Ishii; Y Okamoto
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 8.  The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.

Authors:  Daniëlle Krijgsman; Marianne Hokland; Peter J K Kuppen
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.